Sonnet BioTherapeutics Holdings Total Current Liabilities

Sonnet BioTherapeutics Holdings (SONN) currently reports a total current liabilities of $4.1M as of September 2025. That compares with $3.2M in the prior-year period — up 27.6% year over year. Use the charts on this page to explore Sonnet BioTherapeutics Holdings's total current liabilities history and peer comparisons.

Sonnet BioTherapeutics Holdings's total current liabilities increased from $3.2M to $4.1M — a 27.6% year-over-year increase (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sonnet BioTherapeutics Holdings reported $4.1M in total current liabilities as of September 2025. That compares with $3.2M in the prior-year period — up 27.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $4.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sonnet BioTherapeutics Holdings, and consider following SONN for alerts when major investors trade the stock.

Sonnet BioTherapeutics Holdings is classified in the Consumer Staples sector. On total current liabilities, it currently shows $4.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Staples are usually more informative than comparing SONN with unrelated industries.